key: cord-0688150-k9jsax7u
authors: Di Giacomo, Anna Maria; Giacobini, Gianluca; Gandolfo, Claudia; Lofiego, Maria Fortunata; Cusi, Maria Grazia; Maio, Michele
title: SARS-CoV-2 vaccination and cancer therapy: a successful but mindful mix
date: 2021-08-05
journal: Eur J Cancer
DOI: 10.1016/j.ejca.2021.07.038
sha: c6cf0c94bedad98eba75124a4b240e69addccdf4
doc_id: 688150
cord_uid: k9jsax7u

nan

Cancer patients are commonly considered at higher risk to develop a worse course coronavirus disease 2019 (COVID-19), and to have increased mortality rates due to severe acute respiratory coronavirus 2 (SARS-CoV-2) infection (1, 2) . Thus, screening programs for COVID-19 (3) and preventive vaccination programs against SARS-CoV-2 in frail subjects, have identified cancer patients amongst the earliest populations to be included (4, 5) , with the necessity of high adherence rates (6, 7) .

However, the immunogenicity of SARS-CoV-2 vaccines in cancer patients is still uncertain, and several questions remain to be addressed for the best efficacy of ongoing vaccination campaigns, and to optimally face the prospective risk posed by emerging, more infectious, SARS-CoV-2 variants (8).

Among the many issues one could list are: i, the effectiveness of vaccination on seroconversion of cancer patients compared to healthy individuals; ii, the appropriate timing of vaccination in the course of treatment; iii, the interference on the immunization against SARS-CoV-2 of ongoing anticancer therapies, including their possible differential effect(s); iiii, the immunogenicity of diverse SARS-CoV-2 vaccine types. Providing experimental evidence to elucidate these yet unanswered questions is a priority to eventually optimize the protection of cancer patients from SARS-CoV-2 infection.

To gain an initial understanding on the immunogenicity of SARS-CoV-2 mRNA-based vaccination in patients with solid malignancies on active therapy for their disease, we prospectively investigated levels of circulating anti-SARS-CoV-2 spike IgG antibodies (anti-spike IgG) in vaccinated cancer patients compared to healthy subjects. The potential interference of timing and type of anticancer therapies on anti-spike IgG titers at pre-defined time-points was also evaluated.

Serum samples were collected from consecutive cancer patients (131 subjects) treated on an outpatient basis at our Center with immune-checkpoint(s) inhibitors (ICI) (70 subjects), chemotherapy J o u r n a l P r e -p r o o f (CT) (28 subjects), targeted therapy (TT) (23 subjects), or TT combined with ICI (10 subjects). Main tumor histotypes included skin cancer (57%), thoracic malignancies (22%), and glioblastoma (12%).

Investigated subjects had no history of SARS-CoV-2 infection. As per Institutional guidelines, patients and healthy subjects tested negative to nasopharyngeal swabs within 48 hours prior to Hospital admissions and every ten days, respectively. Patients received a first dose of the mRNA-1273 (Moderna) vaccine (T0), followed by a second dose after 28 days (T1). Vaccine administration was planned and performed at least 7 days apart from the last/next due cycle of therapy. Healthy Hospital personnel (42 subjects) received a first dose of BNT162b2 (Pfizer-BioNTech) vaccine (T0), and a second dose 21 days apart (T1). Sera from blood drawings for routine workup of patients were collected at T0 and T1, and after the second vaccination (T2) (median 18 days; range, 12 to 35); sera from healthy controls were collected at T2 (median 14 days; range, 13 to 29).

As a whole, cancer patients vaccinated with the mRNA-1273 vaccine while on active therapy for their underlying disease, immunized against SARS-CoV-2 alike healthy individuals. Median values of anti-spike IgG at T2 were 17132 arbitrary units per milliliter (AU/ml) (95% confidence interval [CI], 14222 to 25353) and 18064 AU/ml (95% CI, 14270 to 24452), for healthy subjects and cancer patients, respectively (Fig. 1A) . Taken together, this positive finding is undoubtedly encouraging from a practical viewpoint; however, its teaching needs to be balanced and dissected against the type of anticancer therapy that patients receive. Indeed, median values of anti-spike IgG for patients treated with ICI, CT or TT (CT/TT), or TT plus ICI were 1020 AU/ml (95% CI, 814 to 1524), 323 AU/ml (95% CI, 113 to 532) and 605 AU/ml (95% CI, 94 to 4762) at T1, and were 24457 (95% CI, 18064 to 32652), 11086 (95% CI, 7231 to 17168), 18447 (95% CI, 9115 to 35534) at T2, respectively (Fig. 1B) .

Noteworthy, median values of anti-spike IgG were significantly higher for patients receiving ICI J o u r n a l P r e -p r o o f compared to those receiving CT/TT at T1 (P=0.0002) and T2 (P=0.0004) (Fig. 1B) . Additionally, 112 patients (85%) tested positive for anti-spike IgG at T1, while among the 19 patients (15%) who did not develop anti-spike IgG, 3 (16%), 15 (79%), and 1 (5%) were on therapy with ICI, CT, or TT plus ICI, respectively. Lastly, 1 and 4 patients treated with ICI or with CT remained negative for anti-spike IgG also at T2.

As already evident even after the first dose of vaccine, patients on ICI therapy develop significantly higher titers of anti-spike IgG as compared to patients treated with CT/TT, unlike when combined with TT (Fig. 1B) . This improved efficacy of vaccination observed with ICI therapy, compared to CT/TT, is undoubtedly remarkable and of potential prospective usefulness in the daily practice. Though speculative at present, the broad immune-potentiating activity of ICI may likely contribute to the higher anti-spike IgG response observed in ICI treated patients. Thus, the next essential question to be answered will be whether maintained ICI therapy may contribute to sustain with time the very high titers of circulating anti-SARS-CoV-2 antibodies detected after the two "canonical" doses of the mRNA-1273 vaccine. Studies along this line will be fundamental to fully unveil the efficacy of vaccination of cancer patients undergoing ICI therapy as compared to those treated with CT/TT; the long-term immunity to SARS-CoV-2 observed in COVID-19 convalescent healthy subjects supports this need (9) .

According to the comprehensive findings above, numerous practical questions need to be primarily addressed due to the fragility of cancer patients against SARS-CoV-2 infection, and to the need to ameliorate vaccination campaigns in the months ahead. Among these is whether the results observed with the mRNA-1273 vaccine represent a general feature, possibly shared by other mRNA vaccines and/or by non-mRNA SARS-CoV-2 vaccines. Also, the reciprocal interference between timing considered positive when the result was > 50.0 AU/ml. Values higher than 40000 AU/ml were not further investigated and reported as 40000, being the upper limit of the kit detection. All data were represented as median with two-sided 95% confidence intervals were estimated using a normal approximation. Statistical significance for differences between cancer patients and healthy controls was carried out using nonparametric two-sided Mann-Whitney test. With regard to the analysis of

Outcomes of COVID-19 in Patients with Cancer: Report From the National COVID Cohort Collaborative (N3C)

SARS-COV-2 infection in patients with cancer undergoing checkpoint blockade: Clinical course and outcome

Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era

COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials

SARS-CoV-2 vaccines for cancer patients: a call to action

The first report on Covid-19 vaccine refusal by cancer patients in Italy: early data from a single-institute survey

Adherence to COVID-19 vaccines in cancer patients: promote it and make it happen

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

SARS-CoV-2-specific T cell memory is sustained in COVID-19 convalescent patients for 10 months with successful development of stem cell-like memory T cells